BlackRock Inc., 1 of the world’s largest hedge funds, boosted its stake in a clutch of medical device companies, with 1 exception.
Sirona
Sirona gets some Wall Street love with 150% growth in Q4 profits and a new CEO on the way
Sirona Dental Systems (NSDQ:SIRO) gained some points with Wall Street today after posting a strong 4th quarter and 2012 fiscal year earnings report and naming a successor for outgoing CEO Jost Fischer.
SIRO shares were up 7.6% to $61.41 as of about 1 p.m. today after the company held its quarterly earnings call earlier in the morning.
NuVasive’s global sales president is on the way out | Personnel Moves
CareFusion hits 52-week high on Q3 results | Earnings Roundup
CareFusion (NYSE:CFN) hit a 52-week high Friday after beating Wall Street boffins’ predictions for its 3rd-quarter earnings and raising its full-year revenue guidance.
The San Diego-based medical device maker reported profits of $31 million, or 13¢ per diluted share, on sales of $919 million during the 3 months ended March 31, a top-line gain of 9.1%.
Medical Device Tax: Ten companies in line for a whack
The medical device tax set to take effect next year as part of the Affordable Care Act will see all medical device companies pay a 2.3% levy on U.S. sales. But the tax is likely to strike some companies a lot harder where it hurts the most: the bottom line.
AngioDynamics details $372M Navilyst buyout details | Wall Street Beat
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
Sirona’s Q1 sales rise, earnings slide | Earnings Roundup
Sirona (NSDQ:SIRO) shares regained the 1.7% lost Friday after the dental devices maker reported a nearly 10% profit slide for its fiscal 2012 1st quarter.
The Long Island City, N.Y.-based firm reported profits of $38.3 million, or 67 cents per diluted share, on sales of $258.1 million during the 3 months ended Dec. 31, 2011.
That’s a top-line gain of 9.5% compared with profits of $42.4 million, or 75 cents diluted EPS, on sales of $235.6 million during Q1 2011.
Covidien names new vascular leader | Personnel Moves
Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.
Enxing Seng, 47, will lead the division’s 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm’s respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.
Ortho stocks up on strong Q2 prelims for Biomet | Earnings Roundup
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
Allergan beats and raises on 14 percent boost in sales | Earnings Roundup
Allergan Inc. (NYSE:AGN) touted a strong quarter on the back on growing sales.
The Irvine, Calif.-based company saw strong growth in revenue in the three months ended June 30, posting $1.4 billion in sales, which amounts to a 14 percent increase over $1.2 billion in sales reporting during the same time last year.
Device sales jumped 12 percent to $245 million for the quarter, compared to $219 million in Q2 2010.
Sirona’s Q1 net soars as sales grow 20 percent to $31 million
Sirona (NSDQ:SIRO) posted first-quarter sales of $214.8 million for the three months ended Dec. 31, 2009, up 19.5 percent compared with $179.7 million during the same period in 2008. Net income rose 460 percent to $31.2 million, compared with $5.6 million during Q1 2009: